CD44 and neoplasm: Consistent with the above results (Fig. 2E,F), the FH535 treatment significantly suppressed tumor sphere formation (Supplementary Fig. 5A) and the CD44+/CD24− BCSC subpopulation (Supplementary Fig. 5B) in dose-dependent manners.